Rapidly maturing fentanyl clearance in preterm neonates.

Area of Science:

• Neonatal pharmacology
• Clinical pharmacokinetics
• Pediatric intensive care

Background:

• Fentanyl is commonly used off-label in preterm newborns.
• Limited pharmacokinetic data necessitates weight-based dosing, which may be suboptimal.
• This study investigates fentanyl pharmacokinetics in neonates born before 32 weeks gestation.

Purpose of the Study:

• To describe the pharmacokinetic maturation of fentanyl in preterm neonates.
• To develop a population pharmacokinetic model for fentanyl in this population.
• To inform optimized fentanyl dosing strategies for preterm infants.

Main Methods:

• Analysis of 442 plasma samples from 98 preterm neonates.
• Utilized NONMEM V.7.3 for population pharmacokinetic modeling and simulation.
• Included neonates with a median gestational age of 26.9 weeks.

Main Results:

• Fentanyl pharmacokinetics best described by a two-compartment model.
• Clearance significantly influenced by postnatal and gestational age, increasing with age.
• Recommended dose reductions of 50% and 25% for neonates aged 0-4 and 5-9 days, respectively.

Conclusions:

• Bodyweight-based fentanyl dosing may cause accumulation in preterm neonates with low gestational and postnatal ages.
• Dose reduction is crucial for neonates with immature pharmacokinetic profiles.
• Findings support improved fentanyl dosing guidelines for vulnerable preterm infants.